Prevalence and Persistence of Varicella Antibodies in Previously Immunized Children and Youth with Perinatal HIV-1 Infection

Pediatric HIV/AIDS Cohort Study (PHACS), Pediatric HIV/AIDS Cohort Study (PHACS), Pediatric HIV/AIDS Cohort Study (PHACS), Pediatric HIV/AIDS Cohort Study (PHACS), Pediatric HIV/AIDS Cohort Study (PHACS), Pediatric HIV/AIDS Cohort Study (PHACS), Pediatric HIV/AIDS Cohort Study (PHACS), Pediatric HIV/AIDS Cohort Study (PHACS), Pediatric HIV/AIDS Cohort Study (PHACS), Pediatric HIV/AIDS Cohort Study (PHACS), Pediatric HIV/AIDS Cohort Study (PHACS), Pediatric HIV/AIDS Cohort Study (PHACS), Pediatric HIV/AIDS Cohort Study (PHACS), Pediatric HIV/AIDS Cohort Study (PHACS)

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

Background.Two doses of live-attenuated varicella-zoster vaccine are recommended for human immunodeficiency virus 1 (HIV-1)-infected children with CD4% ≥15%. We determined the prevalence and persistence of antibody in immunized children with perinatal HIV (PHIV) and their association with number of vaccinations, combination antiretroviral therapy (cART), and HIV status. Methods.The Adolescent Master Protocol is an observational study of children with PHIV and perinatally HIV-exposed but uninfected (PHEU) children conducted at 15 US sites. In a cross-sectional analysis, we tested participants' most recent stored sera for varicella antibody using whole-cell and glycoprotein enzyme-linked immunosorbent assay. Seropositivity predictors were identified using multivariable logistic regression models and C statistics. Results.Samples were available for 432 children with PHIV and 221 PHEU children; 82% of children with PHIV and 97% of PHEU children were seropositive (P <. 001). Seropositivity after 1 vaccine dose among children with PHIV and PHEU children was 100% at <3 years (both), 73% and 100% at 3-<7 years (P <. 05), and 77% and 97% at ≥7 years (P <. 01), respectively. Seropositivity among recipients of 2 vaccine doses was >94% at all intervals. Independent predictors of seropositivity among children with PHIV were receipt of 2 vaccine doses, receipt of 1 dose while on ≥3 months of cART, compared with none (adjusted odds ratio [aOR]: 14.0 and 2.8, respectively; P <. 001 for overall dose effect), and in those vaccinated ≥3 years previously, duration of cART (aOR: 1.29 per year increase, P =. 02). Conclusions.Humoral immune responses to varicella vaccine are best achieved when children with PHIV receive their first dose ≥3 months after cART initiation and maintained by completion of the 2-dose series and long-term cART use.

Original languageEnglish (US)
Pages (from-to)106-114
Number of pages9
JournalClinical Infectious Diseases
Volume62
Issue number1
DOIs
StatePublished - Jan 1 2016

Keywords

  • HIV
  • antibodies
  • perinatal
  • vaccine
  • varicella

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Prevalence and Persistence of Varicella Antibodies in Previously Immunized Children and Youth with Perinatal HIV-1 Infection'. Together they form a unique fingerprint.

  • Cite this

    Pediatric HIV/AIDS Cohort Study (PHACS), Pediatric HIV/AIDS Cohort Study (PHACS), Pediatric HIV/AIDS Cohort Study (PHACS), Pediatric HIV/AIDS Cohort Study (PHACS), Pediatric HIV/AIDS Cohort Study (PHACS), Pediatric HIV/AIDS Cohort Study (PHACS), Pediatric HIV/AIDS Cohort Study (PHACS), Pediatric HIV/AIDS Cohort Study (PHACS), Pediatric HIV/AIDS Cohort Study (PHACS), Pediatric HIV/AIDS Cohort Study (PHACS), Pediatric HIV/AIDS Cohort Study (PHACS), Pediatric HIV/AIDS Cohort Study (PHACS), Pediatric HIV/AIDS Cohort Study (PHACS), & Pediatric HIV/AIDS Cohort Study (PHACS) (2016). Prevalence and Persistence of Varicella Antibodies in Previously Immunized Children and Youth with Perinatal HIV-1 Infection. Clinical Infectious Diseases, 62(1), 106-114. https://doi.org/10.1093/cid/civ734